Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Financing Activities (2017 - 2025)

Cue Biopharma's Cash from Financing Activities history spans 9 years, with the latest figure at $1000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 99.99% year-over-year to $1000.0; the TTM value through Sep 2025 reached $15.9 million, down 0.56%, while the annual FY2024 figure was $10.2 million, 13.63% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $1000.0 at Cue Biopharma, down from $17.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $27.4 million in Q4 2022 and bottomed at -$1.0 million in Q2 2024.
  • The 5-year median for Cash from Financing Activities is $2.4 million (2024), against an average of $5.9 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 51088.89% in 2023 before it plummeted 147.6% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $7.4 million in 2021, then surged by 271.2% to $27.4 million in 2022, then crashed by 82.55% to $4.8 million in 2023, then tumbled by 119.49% to -$932000.0 in 2024, then soared by 100.11% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Cash from Financing Activities are $1000.0 (Q3 2025), $17.8 million (Q2 2025), and -$1.0 million (Q1 2025).